OrthoPediatrics Corp. (NASDAQ:KIDS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Stanley Muller on Sep 25th, 2026

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $26.44.

Several research firms recently weighed in on KIDS. Piper Sandler reissued an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a report on Wednesday, August 5th. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Finally, Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th.

Read Our Latest Analysis on KIDS

Insider Buying and Selling

In other OrthoPediatrics news, major shareholder Squadron Capital Llc sold 302,369 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the insider directly owned 6,201,764 shares in the company, valued at $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David R. Pelizzon sold 302,369 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the director owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This trade represents a 4.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 2,100,000 shares of company stock valued at $46,747,931. 32.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On OrthoPediatrics

Several institutional investors have recently modified their holdings of the business. Legal & General Group Plc bought a new stake in OrthoPediatrics during the 2nd quarter worth approximately $34,000. Quantinno Capital Management LP bought a new position in OrthoPediatrics in the first quarter valued at approximately $160,000. FourThought Financial Partners LLC acquired a new position in shares of OrthoPediatrics in the fourth quarter valued at approximately $197,000. Waverly Advisors LLC acquired a new position in shares of OrthoPediatrics in the first quarter valued at approximately $184,000. Finally, R Squared Ltd bought a new stake in shares of OrthoPediatrics during the first quarter worth $212,000. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Stock Up 1.4%

NASDAQ:KIDS opened at $22.64 on Friday. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 12-month low of $14.42 and a 12-month high of $26.74. The stock’s fifty day simple moving average is $22.45 and its 200-day simple moving average is $19.34. The firm has a market capitalization of $591.13 million, a P/E ratio of -13.48 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. Equities research analysts expect that OrthoPediatrics will post -1.14 earnings per share for the current year.

About OrthoPediatrics

(Get Free Report)

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.